Senti Biosciences Stock Performance
| SNTI Stock | USD 4.36 0.34 8.46% |
Senti Biosciences holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -1.72, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Senti Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Senti Biosciences is expected to outperform it. Use Senti Biosciences skewness, and the relationship between the value at risk and day median price , to analyze future returns on Senti Biosciences.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Senti Biosciences are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, Senti Biosciences demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.46 | Five Day Return 6.6 | Year To Date Return 14.44 | Ten Year Return (95.63) | All Time Return (95.63) |
Last Split Factor 1:10 | Last Split Date 2024-07-18 |
1 | Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com | 11/20/2024 |
2 | Senti Biosciences, Inc. Announces Oversubscribed 37.6 Million Private Placement Equity Financing | 12/02/2024 |
3 | Senti Biosciences Approves New Employee Stock Options in Latest Inducement Grants SNTI Stock News - StockTitan | 12/03/2024 |
4 | Acquisition by Rajangam Kanya of tradable shares of Senti Biosciences at 2.25 subject to Rule 16b-3 | 12/09/2024 |
5 | Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics | 12/16/2024 |
6 | Acquisition by Rajangam Kanya of 152000 shares of Senti Biosciences at 0.46 subject to Rule 16b-3 | 12/27/2024 |
7 | Senti Bio Announces Additional 11.5 Million of Financing | 01/06/2025 |
8 | Disposition of 1297 shares by Rajangam Kanya of Senti Biosciences at 4.07 subject to Rule 16b-3 | 02/04/2025 |
9 | Disposition of 182 shares by Rajangam Kanya of Senti Biosciences at 4.37 subject to Rule 16b-3 | 02/06/2025 |
| Begin Period Cash Flow | 61 M |
Senti |
Senti Biosciences Relative Risk vs. Return Landscape
If you would invest 209.00 in Senti Biosciences on November 18, 2024 and sell it today you would earn a total of 227.00 from holding Senti Biosciences or generate 108.61% return on investment over 90 days. Senti Biosciences is currently generating 4.9609% in daily expected returns and assumes 47.2323% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Senti, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Senti Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Senti Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Senti Biosciences, and traders can use it to determine the average amount a Senti Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.105
| Best Portfolio | Best Equity | SNTI | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 47.23 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Senti Biosciences is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Senti Biosciences by adding it to a well-diversified portfolio.
Senti Biosciences Fundamentals Growth
Senti Stock prices reflect investors' perceptions of the future prospects and financial health of Senti Biosciences, and Senti Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Senti Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (180.17) % | ||||
| Current Valuation | 45.29 M | ||||
| Shares Outstanding | 4.59 M | ||||
| Price To Book | 1.32 X | ||||
| Price To Sales | 57.44 X | ||||
| Revenue | 2.56 M | ||||
| Gross Profit | (29.78 M) | ||||
| EBITDA | (61.34 M) | ||||
| Net Income | (71.06 M) | ||||
| Cash And Equivalents | 140.78 M | ||||
| Cash Per Share | 3.24 X | ||||
| Total Debt | 37.67 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 8.09 X | ||||
| Book Value Per Share | 14.64 X | ||||
| Cash Flow From Operations | (52.4 M) | ||||
| Earnings Per Share | (15.59) X | ||||
| Market Capitalization | 45.89 M | ||||
| Total Asset | 119.48 M | ||||
| Retained Earnings | (244.34 M) | ||||
| Working Capital | 58.53 M | ||||
| Current Asset | 7.4 M | ||||
| Current Liabilities | 1.05 M | ||||
About Senti Biosciences Performance
By evaluating Senti Biosciences' fundamental ratios, stakeholders can gain valuable insights into Senti Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Senti Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Senti Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 275.62 | 165.99 | |
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (1.00) | (1.05) | |
| Return On Assets | (0.89) | (0.94) | |
| Return On Equity | (1.60) | (1.52) |
Things to note about Senti Biosciences performance evaluation
Checking the ongoing alerts about Senti Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Senti Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Senti Biosciences is way too risky over 90 days horizon | |
| Senti Biosciences appears to be risky and price may revert if volatility continues | |
| Senti Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (71.06 M) with loss before overhead, payroll, taxes, and interest of (29.78 M). | |
| Senti Biosciences currently holds about 140.78 M in cash with (52.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24. | |
| Senti Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 1297 shares by Rajangam Kanya of Senti Biosciences at 4.07 subject to Rule 16b-3 |
- Analyzing Senti Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Senti Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Senti Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Senti Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Senti Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Senti Biosciences' stock. These opinions can provide insight into Senti Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Senti Stock analysis
When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |